Senem Karabulut1, Çiğdem Usul Afsar2, Mehmet Karabulut3, Halil Alış3, Leyla Kılıc1, Murat Çikot3, Ceren Tilgen Yasasever4, Nuri Faruk Aykan1. 1. Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey. 2. Department of Medical Oncology, Istanbul Education and Research Hospital, Istanbul, Turkey. cigdemusul@yahoo.com. 3. Clinic of General Surgery, Istanbul Bakırköy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey. 4. Department of Basic Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey.
Abstract
BACKGROUND: Inflammatory cytokines modulate immune responses in the tumor microenvironment during progression. The role of interleukin (IL-17) in cancer is currently under debate. This study was conducted to investigate the serum levels of IL-17 in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters. MATERIAL AND METHODS: Thirty-five patients with PA were investigated. Serum samples were obtained on first admission before treatment and follow-up. Both serum IL-17 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched 35 healthy controls were included in the analysis. RESULTS: The median age at diagnosis was 61 years, range 38-84 years; 21 (60%) patients were men. The tumor was located in the head of pancreas in 24 (69%) patients. The most common metastatic site was liver in 20 patients with metastasis (n = 18, 90%). The median follow-up time was 24.0 weeks (range 1.0-191.0 weeks). At the end of the observation period, 12 (34%) patients experienced disease progression and 23 patients (66%) were dead. Forty-four percent of 18 metastatic patients who received palliative chemotherapy (CTx) were CTx-responsive. Median progression-free survival and overall survival of the whole group were 13.7 ± 2.3 weeks [95% confidence interval (CI) = 9-18 weeks] and 48.0 ± 12.8 weeks (95% CI = 23-73 weeks), respectively. The baseline serum IL-17 levels were significantly higher in patients with PA than in the control group (p = 0.001). Moreover, serum IL-17 levels were significantly higher in the patients with large pathologic tumor status and low albumin levels (p = 0.04 and p = 0.03, respectively). However, serum IL-17 assays had no prognostic roles on outcome. CONCLUSION: Although serum levels of IL-17 assays were found to be diagnostic value, no predictive and prognostic value was determined in PA patients.
BACKGROUND: Inflammatory cytokines modulate immune responses in the tumor microenvironment during progression. The role of interleukin (IL-17) in cancer is currently under debate. This study was conducted to investigate the serum levels of IL-17 in patients with pancreatic adenocarcinoma (PA) and the relationship with tumor progression and known prognostic parameters. MATERIAL AND METHODS: Thirty-five patients with PA were investigated. Serum samples were obtained on first admission before treatment and follow-up. Both serum IL-17 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched 35 healthy controls were included in the analysis. RESULTS: The median age at diagnosis was 61 years, range 38-84 years; 21 (60%) patients were men. The tumor was located in the head of pancreas in 24 (69%) patients. The most common metastatic site was liver in 20 patients with metastasis (n = 18, 90%). The median follow-up time was 24.0 weeks (range 1.0-191.0 weeks). At the end of the observation period, 12 (34%) patients experienced disease progression and 23 patients (66%) were dead. Forty-four percent of 18 metastatic patients who received palliative chemotherapy (CTx) were CTx-responsive. Median progression-free survival and overall survival of the whole group were 13.7 ± 2.3 weeks [95% confidence interval (CI) = 9-18 weeks] and 48.0 ± 12.8 weeks (95% CI = 23-73 weeks), respectively. The baseline serum IL-17 levels were significantly higher in patients with PA than in the control group (p = 0.001). Moreover, serum IL-17 levels were significantly higher in the patients with large pathologic tumor status and low albumin levels (p = 0.04 and p = 0.03, respectively). However, serum IL-17 assays had no prognostic roles on outcome. CONCLUSION: Although serum levels of IL-17 assays were found to be diagnostic value, no predictive and prognostic value was determined in PA patients.
Authors: J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba Journal: Gene Ther Date: 2015-05-04 Impact factor: 5.250
Authors: Andrew D Rhim; Paul E Oberstein; Dafydd H Thomas; Emily T Mirek; Carmine F Palermo; Stephen A Sastra; Erin N Dekleva; Tyler Saunders; Claudia P Becerra; Ian W Tattersall; C Benedikt Westphalen; Jan Kitajewski; Maite G Fernandez-Barrena; Martin E Fernandez-Zapico; Christine Iacobuzio-Donahue; Kenneth P Olive; Ben Z Stanger Journal: Cancer Cell Date: 2014-05-22 Impact factor: 31.743
Authors: T Kato; H Furumoto; T Ogura; Y Onishi; M Irahara; S Yamano; M Kamada; T Aono Journal: Biochem Biophys Res Commun Date: 2001-04-06 Impact factor: 3.575
Authors: Jennifer L Gnerlich; Jonathan B Mitchem; Joshua S Weir; Narendra V Sankpal; Hiroyuki Kashiwagi; Brian A Belt; Matthew R Porembka; John M Herndon; Timothy J Eberlein; Peter Goedegebuure; David C Linehan Journal: J Immunol Date: 2010-08-30 Impact factor: 5.422
Authors: Linghui Xu; Wanhong Ding; Lori L Stohl; Xi K Zhou; Shayan Azizi; Ethan Chuang; Jimmy Lam; John A Wagner; Richard D Granstein Journal: Immunology Date: 2017-12-20 Impact factor: 7.397